Hansson L, Karlberg B E, Aberg H, Westerlund A, Jameson S, Henningsen N C
Acta Med Scand. 1976;199(4):257-61. doi: 10.1111/j.0954-6820.1976.tb06729.x.
A report is given from an on-going multicenter trial in Sweden, in which 117 hypertensive patients have been treated with a new cardioselective beta-adrenergic blocking agent, atenolol (ICI 66.082, Tenormin) for an average of six months (range 2-21). Statistically significant reductions of BP were observed, recumbent by 29/19 mmHg (p less than 0.0001) and standing by 28/18 mmHg (p less than 0.0001). Few and comparatively mild side-effects were seen.
